Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Webcast: Navigating new frontiers: Ways to find space in the future RA market

April 9, 2019 | Pharma, Webcast, healthcare, rheumatoid arthritis 

In partnership with pharmaphorum

View the webcast »

The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several other candidates reach late-stage development.

Analysis of Therapy Watch data, a real-time syndicated market tracking tool and Living Withdata, our syndicated patient report series shows that JAK inhibitors have already made a strong impression in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake.

This webcast, held in partnership with pharmaphorum uses the latest intelligence from both physicians and patients to look at emerging trends in the RA market, how these will shape the RA market of tomorrow and how companies can best position themselves for future success.

Topics covered in the webcast include:

  • The European RA market
  • Current status and market situation of JAK inhibitors (key EU5 countries)
  • Uptake curve of JAKS compared to other new entrants and biosimilars
  • The patient profile and unmet needs in RA
  • Profile of physicians prescribing JAKS
  • Country differences
  • The future of new classes of JAK inhibitors

View the webcast »

This content was provided by Research Partnership

Company Details

- PMLiVE

Research Partnership

Email
Website

 Latest Content from  Research Partnership 

A guide to measuring and tracking brand KPIs

Dr Allison Fleetwood, Director of Therapy Watch, alongside Associate Director Jennifer Redfearn, recently delivered a workshop on measuring and tracking brand KPIs as part of the BHBIA training programme (www.bhbia.org.uk).

Electronic medical records and doctor/patient communication

View from the US: When I talk to family members or friends who are physicians these days, I hear a lot of complaints.

Statistics and bikinis – 2 men united

I want to write today about 2 men that between them have reminded me of a fine line that we have to tread every time we analyse a dataset...

Eliminating Stigma: A consideration of the role the pharmaceutical industry can play

My recent article in Medical Marketing & Media explored the importance of vaccine perceptions in a self-pay market and touched upon the issue of stigma, with the recognition that some diseases or...

Fighting talk

One thing that grasps my interest is how society has adopted military style language when talking about cancer

Is MINT the next BRIC?

In 2001, British economist Jim O’Neill coined the now ubiquitous acronym ‘BRIC’, to stand for the four emerging economies of Brazil, Russia, India and China, which he suggested were all...

The healthcare market research themes for 2014

As we shake off our winter coats and prepare for what will hopefully be a long, hot summer, the 2014 themes for healthcare and market research are emerging.

Big Data—a new player in the Healthcare Industry

Big Data is an exciting by-product of the information technology revolution and offers new ways of understanding customers.

Blog: Affordable Care Act

What does the future hold for the US pharma industry?

Webinar: How to conduct effective market research in emerging markets

Pharmaceutical market research is still evolving in many emerging markets and so finding the insights you require can be a challenge.